A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Public ClinicalTrials.gov record NCT00112021. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2B, Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
Study identification
- NCT ID
- NCT00112021
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2005
- Primary completion
- Oct 31, 2005
- Completion
- Oct 31, 2005
- Last update posted
- Apr 9, 2015
2005
United States locations
- U.S. sites
- 21
- U.S. states
- 18
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Chula Vista | California | — | — |
| Research Site | San Diego | California | — | — |
| Research Site | Walnut Creek | California | — | — |
| Research Site | Miami | Florida | — | — |
| Research Site | Augusta | Georgia | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Indianapolis | Indiana | — | — |
| Research Site | Overland Park | Kansas | — | — |
| Research Site | Baton Rouge | Louisiana | — | — |
| Research Site | Detroit | Michigan | — | — |
| Research Site | Edina | Minnesota | — | — |
| Research Site | St Louis | Missouri | — | — |
| Research Site | Butte | Montana | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Cincinnati | Ohio | — | — |
| Research Site | Portland | Oregon | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Austin | Texas | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Salt Lake City | Utah | — | — |
| Research Site | Olympia | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00112021, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 9, 2015 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00112021 live on ClinicalTrials.gov.